PMID- 35577837
OWN - NLM
STAT- MEDLINE
DCOM- 20220519
LR  - 20231101
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 May 16
TI  - SARS-CoV-2 in silico binding affinity to human leukocyte antigen (HLA) Class II 
      molecules predicts vaccine effectiveness across variants of concern (VOC).
PG  - 8074
LID - 10.1038/s41598-022-11956-5 [doi]
LID - 8074
AB  - There is widespread concern about the clinical effectiveness of current vaccines 
      in preventing Covid-19 caused by SARS-CoV-2 Variants of Concern (Williams in 
      Lancet Respir Med 29:333-335, 2021; Hayawi in Vaccines 9:1305, 2021), including 
      those identified at present (Alpha, Beta, Gamma, Delta, Omicron) and possibly new 
      ones arising in the future. It would be valuable to be able to predict vaccine 
      effectiveness for any variant. Here we offer such an estimate of predicted 
      vaccine effectiveness for any SARS-CoV-2 variant based on the amount of overlap 
      of in silico high binding affinity of the variant and Wildtype spike 
      glycoproteins to a pool of frequent Human Leukocyte Antigen Class II molecules 
      which are necessary for initiating antibody production (Blum et al. in Annu Rev 
      Immunol 31:443-473, 2013). The predictive model was strong (r = 0.910) and 
      statistically significant (P = 0.013).
CI  - (c) 2022. The Author(s).
FAU - Charonis, Spyros A
AU  - Charonis SA
AD  - The HLA SARS-CoV-2 Research Group, Department of Veterans Affairs Health Care 
      System, Brain Sciences Center (11B), Minneapolis VAHCS, One Veterans Drive, 
      Minneapolis, MN, 55417, USA.
AD  - Department of Neuroscience, University of Minnesota Medical School, Minneapolis, 
      MN, 55455, USA.
FAU - James, Lisa M
AU  - James LM
AD  - The HLA SARS-CoV-2 Research Group, Department of Veterans Affairs Health Care 
      System, Brain Sciences Center (11B), Minneapolis VAHCS, One Veterans Drive, 
      Minneapolis, MN, 55417, USA.
AD  - Department of Neuroscience, University of Minnesota Medical School, Minneapolis, 
      MN, 55455, USA.
FAU - Georgopoulos, Apostolos P
AU  - Georgopoulos AP
AD  - The HLA SARS-CoV-2 Research Group, Department of Veterans Affairs Health Care 
      System, Brain Sciences Center (11B), Minneapolis VAHCS, One Veterans Drive, 
      Minneapolis, MN, 55417, USA. omega@umn.edu.
AD  - Department of Neuroscience, University of Minnesota Medical School, Minneapolis, 
      MN, 55455, USA. omega@umn.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20220516
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (HLA Antigens)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (Vaccines)
RN  - 0 (spike protein, SARS-CoV-2)
RN  - SARS-CoV-2 variants
SB  - IM
MH  - *COVID-19/prevention & control
MH  - HLA Antigens
MH  - Humans
MH  - SARS-CoV-2
MH  - Spike Glycoprotein, Coronavirus/metabolism
MH  - Vaccine Efficacy
MH  - *Vaccines
PMC - PMC9109665
COIS- The authors declare no competing interests.
EDAT- 2022/05/17 06:00
MHDA- 2022/05/20 06:00
PMCR- 2022/05/16
CRDT- 2022/05/16 23:18
PHST- 2022/01/14 00:00 [received]
PHST- 2022/04/26 00:00 [accepted]
PHST- 2022/05/16 23:18 [entrez]
PHST- 2022/05/17 06:00 [pubmed]
PHST- 2022/05/20 06:00 [medline]
PHST- 2022/05/16 00:00 [pmc-release]
AID - 10.1038/s41598-022-11956-5 [pii]
AID - 11956 [pii]
AID - 10.1038/s41598-022-11956-5 [doi]
PST - epublish
SO  - Sci Rep. 2022 May 16;12(1):8074. doi: 10.1038/s41598-022-11956-5.